Role of aztreonam in the treatment of nosocomial pneumonia in the critically ill surgical patient

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

In 1995 the American Thoracic Society issued an official consensus statement on the treatment of hospital-acquired pneumonia (HAP). Classes of antimicrobials included in the list of antimicrobials deemed to be suitable for the empiric treatment of severe HAP were the aminoglycosides, quinolones, antipseudomonal penicillins, carbapenems, and β-lactam/β-lactamase inhibitor combinations. Aztreonam, a monobactam, was also listed and is unique among these agents based on its spectrum of activity being limited to the gram-negative bacillary bacteria combined with an excellent safety profile. This review focuses on the role of aztreonam in the treatment of nosocomial pneumonia in the critically ill patient. A review of the literature was performed using PubMed and secondary literature sources as to the clinical efficacy of aztreonam in the treatment of lower respiratory tract infections as well as its pharmacokinetic and safety profiles. An analysis of aztreonam's potential pharmacoeconomic advantages compared with other agents was also performed. Numerous studies have documented that aztreonam has effectiveness that is equal or superior to that of other suitable antibiotics in the treatment of nosocomial pneumonia. Its excellent safety profile makes it a particularly attractive agent compared with the aminoglycosides. Considering the potential costs of bacterial resistance from the use of broader-spectrum alternatives, a case can be made that aztreonam is a pharmacoeconomically sound choice as well. (C) 2000 by Excerpta Medica, Inc.

Original languageEnglish (US)
Pages (from-to)45-50
Number of pages6
JournalAmerican Journal of Surgery
Volume179
Issue number2 SUPPL. 1
DOIs
StatePublished - Jan 1 2000

Fingerprint

Aztreonam
Critical Illness
Pneumonia
Aminoglycosides
Safety
Therapeutics
Monobactams
Lactams
Pharmaceutical Economics
Carbapenems
Quinolones
Gram-Negative Bacteria
PubMed
Respiratory Tract Infections
Penicillins
Pharmacokinetics
Anti-Bacterial Agents
Costs and Cost Analysis

All Science Journal Classification (ASJC) codes

  • Surgery

Cite this

Role of aztreonam in the treatment of nosocomial pneumonia in the critically ill surgical patient. / Boucher, Bradley.

In: American Journal of Surgery, Vol. 179, No. 2 SUPPL. 1, 01.01.2000, p. 45-50.

Research output: Contribution to journalArticle

@article{68f2f43826294b49938426d7e2a38cb1,
title = "Role of aztreonam in the treatment of nosocomial pneumonia in the critically ill surgical patient",
abstract = "In 1995 the American Thoracic Society issued an official consensus statement on the treatment of hospital-acquired pneumonia (HAP). Classes of antimicrobials included in the list of antimicrobials deemed to be suitable for the empiric treatment of severe HAP were the aminoglycosides, quinolones, antipseudomonal penicillins, carbapenems, and β-lactam/β-lactamase inhibitor combinations. Aztreonam, a monobactam, was also listed and is unique among these agents based on its spectrum of activity being limited to the gram-negative bacillary bacteria combined with an excellent safety profile. This review focuses on the role of aztreonam in the treatment of nosocomial pneumonia in the critically ill patient. A review of the literature was performed using PubMed and secondary literature sources as to the clinical efficacy of aztreonam in the treatment of lower respiratory tract infections as well as its pharmacokinetic and safety profiles. An analysis of aztreonam's potential pharmacoeconomic advantages compared with other agents was also performed. Numerous studies have documented that aztreonam has effectiveness that is equal or superior to that of other suitable antibiotics in the treatment of nosocomial pneumonia. Its excellent safety profile makes it a particularly attractive agent compared with the aminoglycosides. Considering the potential costs of bacterial resistance from the use of broader-spectrum alternatives, a case can be made that aztreonam is a pharmacoeconomically sound choice as well. (C) 2000 by Excerpta Medica, Inc.",
author = "Bradley Boucher",
year = "2000",
month = "1",
day = "1",
doi = "10.1016/S0002-9610(00)00321-4",
language = "English (US)",
volume = "179",
pages = "45--50",
journal = "American Journal of Surgery",
issn = "0002-9610",
publisher = "Elsevier Inc.",
number = "2 SUPPL. 1",

}

TY - JOUR

T1 - Role of aztreonam in the treatment of nosocomial pneumonia in the critically ill surgical patient

AU - Boucher, Bradley

PY - 2000/1/1

Y1 - 2000/1/1

N2 - In 1995 the American Thoracic Society issued an official consensus statement on the treatment of hospital-acquired pneumonia (HAP). Classes of antimicrobials included in the list of antimicrobials deemed to be suitable for the empiric treatment of severe HAP were the aminoglycosides, quinolones, antipseudomonal penicillins, carbapenems, and β-lactam/β-lactamase inhibitor combinations. Aztreonam, a monobactam, was also listed and is unique among these agents based on its spectrum of activity being limited to the gram-negative bacillary bacteria combined with an excellent safety profile. This review focuses on the role of aztreonam in the treatment of nosocomial pneumonia in the critically ill patient. A review of the literature was performed using PubMed and secondary literature sources as to the clinical efficacy of aztreonam in the treatment of lower respiratory tract infections as well as its pharmacokinetic and safety profiles. An analysis of aztreonam's potential pharmacoeconomic advantages compared with other agents was also performed. Numerous studies have documented that aztreonam has effectiveness that is equal or superior to that of other suitable antibiotics in the treatment of nosocomial pneumonia. Its excellent safety profile makes it a particularly attractive agent compared with the aminoglycosides. Considering the potential costs of bacterial resistance from the use of broader-spectrum alternatives, a case can be made that aztreonam is a pharmacoeconomically sound choice as well. (C) 2000 by Excerpta Medica, Inc.

AB - In 1995 the American Thoracic Society issued an official consensus statement on the treatment of hospital-acquired pneumonia (HAP). Classes of antimicrobials included in the list of antimicrobials deemed to be suitable for the empiric treatment of severe HAP were the aminoglycosides, quinolones, antipseudomonal penicillins, carbapenems, and β-lactam/β-lactamase inhibitor combinations. Aztreonam, a monobactam, was also listed and is unique among these agents based on its spectrum of activity being limited to the gram-negative bacillary bacteria combined with an excellent safety profile. This review focuses on the role of aztreonam in the treatment of nosocomial pneumonia in the critically ill patient. A review of the literature was performed using PubMed and secondary literature sources as to the clinical efficacy of aztreonam in the treatment of lower respiratory tract infections as well as its pharmacokinetic and safety profiles. An analysis of aztreonam's potential pharmacoeconomic advantages compared with other agents was also performed. Numerous studies have documented that aztreonam has effectiveness that is equal or superior to that of other suitable antibiotics in the treatment of nosocomial pneumonia. Its excellent safety profile makes it a particularly attractive agent compared with the aminoglycosides. Considering the potential costs of bacterial resistance from the use of broader-spectrum alternatives, a case can be made that aztreonam is a pharmacoeconomically sound choice as well. (C) 2000 by Excerpta Medica, Inc.

UR - http://www.scopus.com/inward/record.url?scp=0034055328&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034055328&partnerID=8YFLogxK

U2 - 10.1016/S0002-9610(00)00321-4

DO - 10.1016/S0002-9610(00)00321-4

M3 - Article

VL - 179

SP - 45

EP - 50

JO - American Journal of Surgery

JF - American Journal of Surgery

SN - 0002-9610

IS - 2 SUPPL. 1

ER -